Issues related to the development of gene therapies for rare diseases
2025 · 1st Quarter (Jan 1 - Mar 31)
SPARK THERAPEUTICS, INC.
Filed by BROWNSTEIN HYATT FARBER SCHRECK, LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- BROWNSTEIN HYATT FARBER SCHRECK, LLP
- Client
- SPARK THERAPEUTICS, INC.
- Filing UUID
- 9ec357ac-7918-4e21-9faf-a5e44abfd164
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.